BlinkLab ASX: BB1 Partners with Mental Care Group for ADHD Diagnostics

BlinkLab Limited (ASX: BB1) has partnered strategically with Mental Care Group (MCG), Europe's fifth-largest outpatient mental health care provider, to enhance ADHD diagnostics. This partnership follows positive results from an initial clinical trial involving 184 participants, which validated BlinkLab’s technology. The BlinkLab app quantifies sensory sensitivity in children with ADHD by measuring sound-evoked eyelid responses. This collaboration aims to accelerate BlinkLab’s path to European and US regulatory approval and clinical adoption.

MCG will integrate BlinkLab’s app to improve diagnostic accuracy and efficiency, potentially reducing diagnosis time and improving treatment outcomes. The agreement includes exclusivity in the Netherlands for ADHD, depression, and anxiety disorders and will extend for at least two years following clinical validation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com